NATURAL HISTORY OF HCV INFECTION IN DRUG USERS

吸毒者 HCV 感染的自然史

• 批准号: 6523205
• 负责人: Robert Stephen Klein
• 金额: $ 70.86万
• 依托单位: MONTEFIORE MEDICAL CENTER (BRONX, NY)
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-30 至 2004-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6523205
• 关键词: HIV infections; antiAIDS agent; antiviral antibody; clinical research; disease /disorder proneness /risk; genotype; hepatitis C; hepatotoxin; human genetic material tag; human subject; human therapy evaluation; immunity; interview; intravenous drug abuse; longitudinal human study; pathologic process; psychometrics; sex behavior; substance abuse related behavior; virus RNA; virus genetics; virus infection mechanism; virus load

Hepatitis C virus (HCV) infection is a major cause of morbidity and mortality. Injection drug users have the highest prevalence of HCV infection among all populations in the U.S. at risk. We will study prospectively the natural history of HCV infection among all populations in the U.S. at risk. We will study prospectively the natural history of HCV infection in a cohort of drug users with or at risk for HIV infection. Subjects will be recruited from among participants already enrolled in a large longitudinal study of the natural history of HIV infection in drug users. We will, therefore, be able to take advantage of the large and complex sets of data being collected in that study, and we will be able to link new data that will be collecting on the natural history of HCV infection with those data. Participants will have detailed standardized interviews on demographics, medical history, sexual and drug use behaviors, HIV and immunological testing, and testing for HCV infection, including quantitative HCV RNA levels, including quantitative HCV RNA levels, HCV genotyping, anti-HCV antibodies and, in a subset of participants, HCV sequencing. Persons found to have HCV infection will be referred to the study hepatologist to be evaluated for liver disease and they will be offered standard medical therapy for their HCV infection. Our aims are to determine 1) the effects of HIV infection and its associated immunodeficiency, HCV genotype, and drug use behaviors on HCV viral load and progression of liver disease, 2) the effects of HIV infection and immunodeficiency on response to therapy for HCV infection, 3) the effects of highly active anti-retroviral therapy and control of HIV viral load on the natural history of HCV infection, and 4) whether genetic diversity of HCV is facilitated by immunodeficiency.

丙型肝炎病毒（HCV）感染是发病率和死亡率的主要原因。注射吸毒者在美国所有人群中的HCV感染率最高。我们将前瞻性地研究美国所有人口中HCV感染的自然史。我们将在一系列有艾滋病毒感染风险或有风险的吸毒者中前瞻性地研究HCV感染的自然史。将从已经参加了对吸毒者艾滋病毒感染自然病史的大规模纵向研究的参与者中招募受试者。 因此，我们将能够利用该研究中收集的大型且复杂的数据集，我们将能够将有关HCV感染自然历史的新数据与这些数据联系起来。参与者将进行有关人口统计学，病史，性和药物使用行为，HIV和免疫学测试的详细标准化访谈，以及对HCV感染的测试，包括定量HCV RNA水平，包括定量HCV RNA水平，HCV基因分型，抗HCV抗体，抗HCV抗体和参与者的子集，HCV抗体。发现患有HCV感染的人将被转诊至研究肝病学家以进行肝病评估，并将为其HCV感染提供标准的医疗疗法。我们的目的是确定1）HIV感染及其相关的免疫缺陷，HCV基因型和药物使用行为对HCV病毒负荷和肝病的进展的影响，2）2）HIV感染和免疫缺陷对HCV感染治疗反应的影响，HCV感染对HCV感染的反应，3）高度活跃的抗逆转录病毒疗法和对照4的影响。 HCV的遗传多样性通过免疫缺陷促进。